What if?
<br>You could eliminate pre procedural steps for large bore vascular closure?, <br> You could heal and seal the arteriotomy from the inside?, <br> You could improve vascular complications?

What if?
<br>You could eliminate pre procedural steps for large bore vascular closure?, <br> You could heal and seal the arteriotomy from the inside?, <br> You could improve vascular complications?

Clinical Need

Large arteriotomy management is a unique challenge.
A fully percutaneous approach has become the standard of care for most structural heart and aortic vascular procedures. There is increasing awareness that large catheter sizes can create unique challenges that require a dedicated closure solution.

Play Video


Designed for

Suitable for arteriotomies up to 24F
No pre-procedural steps – OTW delivery
One device per arteriotomy
Fully synthetic absorbable implant
No sutures, no collagen, no metal

Simple and secure
device deployment

Automatic loading – Simple and intuitive delivery
Safety Guidewire remains in situ until implant release
Dedicated 0.035” compatible introducer

Patch based fully
absorbable implant

Ultra-low profile patch, rapidly endothelialised¹
Implant fully absorbed within 180 days¹
Abluminal surface matrix promotes adherence and healing¹

Implant fully absorbed within 180 days¹

Vessel remains patent - restored to its pre-procedure state

Implanted Patch


Implant Fully Encapsulated


Implant extra-vascular-vessel remodeling


Implant fully absorbed - vessel restored

Clinical Evidence

Frontier clinical programmes - An evolving database of safety and effectiveness

Closures across Frontier I-IV studies²
0 %
Technical success rate²
Major procedure related complication²
100 %
No late major or minor complication²


1. Pre-clinical data – on file at Vivasure Medical

2. Clinical data Frontier I-IV studies on file at Vivasure Medical

About Us

Vivasure Medical Limited is a highly innovative medical device company based in the heart of Europe’s largest medtech hub in Galway, Ireland. The company develops advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery.

Established in 2009, Vivasure operates a fully integrated, ISO 13485 certified, R&D and manufacturing facility. The company is staffed by an experienced team of medical device professionals with expertise spanning research, engineering, material science, quality, regulatory, manufacturing, clinical and commercial roles.

Board of Directors

Bernard Collins

Bernard Collins

As the chairman and an independent non-executive director of Vivasure Medical, Dr Bernard Collins brings a wealth of business experience. He serves on the Board of Directors of several U.S. and Irish life-science companies. Prior to forming Lifemed, his consultancy company, Dr Collins served for 10 years as Vice President of International Operations at Boston Scientific Corporation and before this held senior executive positions in life-science companies including Baxter Corporation. His general management experience in the medical device and health care industry spans start-ups, turnarounds, leveraged buyouts and IPOs for both large and small businesses.

Dr Collins holds a BA Honors in Applied Industrial Psychology/Business from University College Cork, Ireland and an honorary Doctorate in Law from the National University of Ireland Galway. He is a recipient of the prestigious RDS Gold Medal for Industry in recognition of his extraordinary contribution to the development of the biomedical industry in Ireland.



Gerard Brett

Gerard Brett


Gerard has over 25 years international business management experience, 20 years in Medtech. Previously, he worked in the USA with Ciba-Geigy Corporation and with Boston Scientific in R&D, technology transfer and operations management. While with Boston, he was responsible for managing the transfer of over 25 vascular product lines into the Galway facility, and played a key role in the integration of the Schneider production into Galway. He co-founded Zerusa Limited, where as CEO he led the development and commercialisation of its Guardian® hemostasis technology in the EU and USA, prior to Zerusa’ s acquisition by Vascular Solutions.

Barbara Castellano

Barbara Castellano

Barbara Castellano is a partner in Panakès Partners. She has more than 20 years of experience in Medtech, in particular in Cardiovascular, having held corporate senior positions at Sorin (now Livanova) and CID Cardiovascular (now Alvimedica).

By leading strategic marketing, business development, clinical, quality and regulatory departments, Barbara developed and brought innovative cardiovascular technologies to the market. More recently, as CEO of the advisory firm TechWald SpA, she has developed strong experience in the Medtech startup world, successfully raising over €15m in venture capital funding for innovative European and Israeli medical technology companies.

Barbara holds a degree in Medicinal Chemistry and an Executive MBA (both magna cum laude) from SDA Bocconi in Milan.


Robert (Chip) Hance

Robert (Chip) Hance

Robert (Chip) Hance is the former CEO of Creganna Medical, an Ireland-based medical device company with over 2,000 employees worldwide that was acquired by TE Connectivity in 2016. In 2012-13, Chip was an Entrepreneur-in-Residence at the Center for Devices and Radiological Health within the United States Food and Drug Administration (FDA), where he co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.

Prior to his FDA experience, Chip was most recently President of Abbott Vascular, the cardiovascular device division of Abbott. Over a decade in interventional cardiology at Abbott Vascular, he led the organization to global leadership in the drug-eluting stent market through the launch of Xience in the U.S., Japan and China. Chip also led the development and CE marking of Absorb, a bioabsorbable scaffold for the treatment of coronary disease and the acquisition and international expansion of Mitraclip, a percutaneous mitral valve repair device.

Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School


Justin Lynch

Justin Lynch

Justin Lynch is a partner in Fountain Healthcare Partners and also serves as the CFO of the firm. He joined the team prior to the launch of Fund I in 2008. Justin has a BA in Accounting & Finance from Dublin City University, an MBA from Trinity College Dublin and is a member of the Chartered Institute of Management Accountants. He has over 25 years of experience in capital markets, corporate finance, entrepreneurial and venture investing across multiple sectors, the latter half in life science. Justin has a particular interest in the medical device sector and led the firm’s investments in Vivasure Medical and in Neuravi where he also serves as a board member.

Anne Portwich

Anne Portwich

Anne Portwich, PhD, is a Partner of LSP, an independent European investment firm, providing financing for private and public life sciences and healthcare companies. With over €2 billion under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s leading life sciences investor. Anne currently serves on the supervisory boards of iSTAR Medical, OneProjects, Atlantic Therapeutics, MedEye, ViCentra and Vivasure Medical. Previous board positions include Sapiens Steering Brain Stimulation (acquired by Medtronic in 2014), ActoGeniX (acquired by Intrexon in 2015), Nexstim (IPO in 2014) and Neuravi (acquired by Codman Neuro in 2017). Prior to joining LSP, Anne was a scientist and project leader at OctoPlus, a Dutch company offering advanced research services to pharmaceutical and biotechnology companies. She obtained an MSc in biochemistry from the University of Hanover and received her PhD from the Max Planck-Society.


Mark Redshaw

Mark Redshaw

Mark Redshaw is an Investment Director at Evonik Venture Capital. Where he focuses on deals relating to nutrition, health and care, and specialty additives. Mark holds board seats at a number of portfolio companies. Prior to joining the team founding Evonik Venture Capital in 2012, Mark held positions within the Nutrition & Care business of Evonik. This included time responsible for sustainability, heading the Evonik’s global Animal Nutrition Services and running the operative business in Africa and the Middle East. Mark studied agriculture at the University of Reading and received a PhD from the University of Nottingham.

David Hochman

David Hochman

David Hochman has served as Chairman and Chief Executive Officer of Orchestra BioMed since May 2018. From 2006 to 2019, he was Managing Partner of Orchestra Medical Ventures, a medical technology venture capital firm. He also served as President of Accelerated Technologies, Inc., a medical device accelerator company managed by Orchestra. David has over 23 years of healthcare entrepreneurial, venture capital and investment banking experience. He is also Chairman of the Board of Motus GI (NASDAQ: MOTS). He was a co-founder and served as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage biopharmaceutical company, from 2013 to 2020. Prior to joining Orchestra Medical Ventures, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc. during which time he led financing transactions for over twenty early-stage companies raising over $420 million. From 1999 to 2006, Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and board member of PROLOR Biotech, Inc., a biopharmaceutical company developing longer lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. He currently serves as President of the Board of the Mollie Parnis Livingston Foundation. He has a B.A. degree with honors from the University of Michigan.


Board Observer

Our Partners

Phone or Fax

Tel: +353 91 395 440
Fax: +353 91 395 399


Parkmore Business Park West
H91 V3KP